An interventional study of Acupuncture needles in Non-erosive Reflux Disease (NERD), sponsored by Nanyang Technological University. Not yet recruiting at 1 site in Singapore. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Nanyang Technological University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:
Participants will:
47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.
This study's planned enrollment of 96 is below the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.
Browse Non-Erosive Reflux Disease studies →Nanyang Technological University is the lead sponsor of 53 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Structural or organic gastrointestinal disease, including but not limited to:
Use of prohibited medical treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min.
Device: Acupuncture needles
The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention.
Device: Acupuncture needles
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
≥ 50% reduction in total GERD-Q score or normalization (\<8)
Time frame: From enrollment to the end of follow-up at 16 weeks
Gastrointestinal Symptom Rating scale (GSRS)
≥ 0.5 point decrease in mean GSRS Reflux domain value
Time frame: From enrollment to the end of follow-up at 16 weeks
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
≥ 0.5 point improvement on the mean QOLRAD score
Time frame: From enrollment to the end of follow-up at 16 weeks
Euro QoL (EQ-5D-5L)
change in index utility
Time frame: From enrollment to the end of follow-up at 16 weeks
Hospital Anxiety and Depression Scale (HADS)
categorical shift from ≥ 11 to \< 11 or ≥ 8 to \< 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale
Time frame: From enrollment to the end of follow-up at 16 weeks
Visceral Sensitivity Index (VSI)
≥ 15% reduction from baseline
Time frame: From enrollment to the end of follow-up at 16 weeks
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
≥ 15% reduction from baseline
Time frame: From enrollment to the end of follow-up at 16 weeks
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
Time frame: At baseline
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100%
Time frame: From enrollment to the end of follow-up at 16 weeks
Bang's blinding index (BBI)
Time frame: End of first week and sixth week of intervention
James' blinding index (JBI)
Time frame: End of first week and sixth week of intervention
Patient's global impression of change (PGIC)
Time frame: From mid-treatment to the end of follow-up at 16 week
Daily patient diary
Time frame: From enrollment to the end of follow-up at 16 weeks
Plan to share: Yes — IPD sharing will be available upon request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will become available within 7 years after completion of the clinical trial.
Access criteria: Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanyang Technological University